SCHEMBL29232148

SCHEMBL29232148

Cn1c(CN2CCN(c3ccccc3C(=O)O)CC2)nc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 13/20 0.68
DRD4 P21917 10/20 0.64
CXCR3 P49682 1/20 0.60
LMNA P02545 3/20 0.58
GAA P10253 2/20 0.58
POLB P06746 1/20 0.58
MAPK1 P28482 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
KDM4E B2RXH2 1/20 0.58
OPRM1 P35372 1/20 0.58
OPRD1 P41143 1/20 0.58
MAPT P10636 1/20 0.56
GFER P55789 1/20 0.56
CHRM5 P08912 1/20 0.56
CHRM1 P11229 1/20 0.56
DRD2 P14416 3/20 0.55
DRD3 P35462 3/20 0.55
ALDH1A1 P00352 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HDAC6 Q9UBN7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24984557 0.90 GRM2 (0.67) GRM2DRD4CXCR3LMNAGAA
SCHEMBL30163906 0.88 GRM2 (0.64) GRM2DRD4CXCR3LMNAGAA
SCHEMBL24984230 0.85 GRM2 (0.67) GRM2DRD4CXCR3LMNAGAA
SCHEMBL24984556 0.84 GRM2 (0.60) GRM2DRD4CXCR3LMNAGAA
SCHEMBL30164209 0.84 GRM2 (0.60) GRM2DRD4CXCR3LMNAGAA
SCHEMBL4143642 0.82 GRM2 (0.76) GRM2DRD4CXCR3LMNAGAA
SCHEMBL4151427 0.82 GRM2 (0.76) GRM2DRD4CXCR3LMNAGAA
SCHEMBL5156990 0.81 GRM2 (0.81) GRM2DRD4LMNAGAAPOLB
SCHEMBL4139885 0.81 GRM2 (1.00) GRM2DRD4CXCR3LMNAGAA
SCHEMBL4138559 0.80 GRM2 (1.00) GRM2DRD4LMNAGAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118159530-A Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling 康福治疗有限公司 2024-06-07 CN disclosed